Capricorn Fund Managers Ltd Takes $4.87 Million Position in Kenvue Inc. $KVUE
Capricorn Fund Managers Ltd initiated a new position in Kenvue Inc. (NYSE:KVUE) during the fourth quarter, acquiring 282,485 shares valued at approximately $4.87 million. Kenvue exceeded Q4 earnings and revenue estimates and offers a 4.8% dividend yield, while institutional ownership is high at 97.64%. Analysts currently maintain a consensus "Hold" rating with an average target price near $19.58.
T. Rowe Price Spectrum Moderate Growth Allocation Fund's Kenvue Inc(KVUE) Holding History
This article details T. Rowe Price Spectrum Moderate Growth Allocation Fund's historical holdings in Kenvue Inc (KVUE). It states that the fund currently holds 0 shares of KVUE, with a 0% portfolio allocation and 0% total estimated gain. The article also lists recent news articles related to Kenvue Inc (KVUE).
141,900 Shares in Kenvue Inc. $KVUE Bought by Cohen Capital Management Inc.
Cohen Capital Management Inc. recently acquired 141,900 shares of Kenvue Inc. ($KVUE) in the fourth quarter, totaling approximately $2.45 million. Kenvue exceeded quarterly earnings expectations with $0.27 EPS and $3.78 billion in revenue, while institutional investors hold about 97.64% of the company's stock. Analysts generally maintain a "Hold" rating on Kenvue with an average price target of $19.58, and the company offers an annualized dividend of $0.83, yielding approximately 4.8%.
Kenvue Inc. (KVUE) stock price, news, quote and history
This article provides comprehensive financial information for Kenvue Inc. (KVUE), including real-time stock price data, historical performance, key financial metrics, and analyst ratings. It details the company's business segments, primary brands, and lists comparable companies in the Household & Personal Products industry. The summary highlights Kenvue's stock performance relative to the S&P 500 and its valuation measures as of early April 2026.
Do Not Build a Retirement Portfolio in 2026 Without at Least One of These 3 Dividend Kings
This article highlights three "Dividend King" stocks—PepsiCo (PEP), Federal Realty Investment Trust (FRT), and Kimberly-Clark (KMB)—as essential for retirement portfolios in 2026. These companies offer consistent dividend growth, high yields, and are currently trading at attractive valuations after market adjustments. The author argues that they provide stability and inflation hedging, balancing portfolios that might be overly exposed to tech or seeking compounding returns.
Jeffrey Smith (KVUE) grows deferred share units to 15,123.688
Kenvue Inc. director Jeffrey C. Smith reported the acquisition of 1,331 Deferred Share Units (DSUs) through a routine compensation grant, increasing his total direct holdings to 15,123.688 DSUs. These units, which include shares from dividend reinvestment, will be settled in Kenvue common stock upon his separation from board service. Additionally, investment funds managed by Starboard Value LP, where Smith is a managing member, indirectly hold over 27 million shares of Kenvue common stock.
The New Blue-Chip: How Johnson & Johnson Refined Its Empire for a High-Growth Future
Johnson & Johnson has transformed from a consumer-facing conglomerate into a "pure-play" healthcare powerhouse, focusing solely on Innovative Medicine and MedTech after divesting its consumer health business. Under CEO Joaquin Duato, the company is prioritizing high-margin medical breakthroughs, aggressive M&A, and digital integration. Despite legal challenges and patent cliffs, J&J maintains a strong financial position, robust growth prospects, and consistent investor returns, with a strategic focus on robotic surgery and pharmaceutical pipeline acceleration.
Kenvue Defends ORSL, ERZL Amid Misinformation Concerns, Reaffirms Science-Backed Hydration Strategy
Kenvue is addressing misinformation surrounding its hydration brands ORSL and ERZL, as well as the ingredient sucralose, by reaffirming its commitment to science-backed products and ethical practices. The company emphasized its dual-brand strategy where ORSL targets diarrheal dehydration and ERZL focuses on everyday hydration, and highlighted the scientific evaluation and safety recognition of sucralose by global and Indian regulatory bodies. Kenvue also noted a reformulation of its ERZL electrolyte drinks with 87% less added sugar and 1.4 times more electrolytes to align with evolving health priorities.
Kenvue (KVUE) director Richard Allison awarded 1,331 deferred share units
Kenvue Inc. director Richard E. Allison Jr. was granted 1,331 Deferred Share Units (DSUs) as non-cash board compensation. These DSUs, which represent the right to receive one share of common stock each, will be settled in shares after his departure from the board. Following this award, his total DSU balance stands at 37,634.229 units, including those from dividend reinvestment.
Kenvue Inc. $KVUE Shares Sold by Wealth Enhancement Advisory Services LLC
Wealth Enhancement Advisory Services LLC significantly reduced its stake in Kenvue Inc. (KVUE) by 41.3% in Q4, selling 197,170 shares. Despite Kenvue beating earnings and revenue estimates for the quarter and offering a 4.8% dividend yield, analyst consensus remains a "Hold" with an average target price of $19.58, and Jefferies downgraded the stock from "Buy" to "Hold." The company's high payout ratio of 107.79% and institutional ownership of 97.64% are also noteworthy.
A Look At Edgewell Personal Care (EPC) Valuation After ESOP-Linked Shelf Registration Filing
Edgewell Personal Care (EPC) has filed a US$45.701 million shelf registration for up to 2,300,000 common shares tied to its Employee Stock Ownership Plan, raising questions about potential dilution. Despite recent share price gains, the longer-term momentum has been weaker, and the market views the stock as modestly undervalued at $21.43 against a narrative fair value of $24.33. The valuation hinges on a sharp earnings reset and margin rebuild through sustained productivity and cost efficiency initiatives.
Kenvue Inc (KVUE) Stock Price Quote Today & Current Price Chart
This article provides a stock price quote and current price chart for Kenvue Inc. (KVUE), the consumer health spin-off of Johnson & Johnson. It details trading conditions for KVUE CFDs, including spreads, overnight funding adjustments, and margin requirements. The article also provides key financial stats for Kenvue and mentions its portfolio of well-known brands like Tylenol, Band-Aid, and Neutrogena.
Kenvue Inc (KVUE) Stock Price Quote Today & Current Price Chart
This article provides a stock price quote and current price chart for Kenvue Inc (KVUE), the consumer health spin-off of Johnson & Johnson, known for brands like Tylenol and Neutrogena. It details CFD trading conditions, including spreads, overnight funding adjustments, and margin requirements. The content also features recent articles related to other company stock forecasts, such as Amazon, Siemens, Microsoft, and HENSOLDT.
Kenvue Inc (KVUE) Stock Price Quote Today & Current Price Chart
This article provides current stock price information and trading conditions for Kenvue Inc. (KVUE), the consumer health spin-off of Johnson & Johnson. It outlines CFD trading details such as spread, overnight funding adjustments, and commission, alongside key financial stats like previous close and 1-year change. The company is highlighted for its iconic brands and stable cash flows.
Beacon Investment Advisory Services Inc. Sells 58,696 Shares of Kenvue Inc. $KVUE
Beacon Investment Advisory Services Inc. reduced its stake in Kenvue Inc. (NYSE:KVUE) by 12.6% in the fourth quarter, selling 58,696 shares but still holding 408,412 shares valued at approximately $7.05 million. Despite other institutional investors increasing their positions, Wall Street analysts currently rate Kenvue as a "Hold" with an average price target of $19.58. Kenvue's recent earnings beat estimates, and it offers a quarterly dividend yielding about 4.7%, though its payout ratio raises potential sustainability concerns.
Kenvue Stock: Consumer Health Leader's Business Model, Competitive Position, and Investor Outlook IS
Kenvue Inc., spun off from Johnson & Johnson, is a consumer health giant known for brands like Tylenol and Neutrogena. The company operates through Self Care, Skin Health and Beauty, and Essential Health segments, maintaining a strong position in North American markets with its iconic brands and resilient business model. This article explores Kenvue's competitive advantages, sector drivers, and investor outlook, highlighting its potential for stable growth and dividend appeal for North American portfolios.
124,000 Shares in Kenvue Inc. $KVUE Acquired by CIBRA Capital Ltd
CIBRA Capital Ltd recently acquired 124,000 shares of Kenvue Inc. (NYSE:KVUE) in the fourth quarter, valued at approximately $2.14 million, making it their 12th largest holding. Kenvue has outperformed recent earnings estimates and offers a dividend yield of 4.7%, despite a high payout ratio. Analysts currently hold a "Hold" consensus rating for KVUE, with an average price target of $19.58, following mixed adjustments from various firms.
DLK Investment Management LLC Sells 67,219 Shares of Kenvue Inc. $KVUE
DLK Investment Management LLC reduced its stake in Kenvue Inc. (NYSE:KVUE) by 39.6% in the fourth quarter, selling 67,219 shares to hold 102,727 shares valued at $1,772,000. Other institutional investors have also adjusted their positions in Kenvue, with some increasing their holdings. Analysts currently have an average "Hold" rating for Kenvue with a target price of $19.58, following recent earnings that beat estimates and a declared quarterly dividend.
Wolff Wiese Magana LLC Has $73,000 Stake in Kenvue Inc. $KVUE
Wolff Wiese Magana LLC significantly reduced its stake in Kenvue Inc. (NYSE:KVUE) by 94.7% in the fourth quarter, selling 75,052 shares and retaining 4,205 shares valued at $73,000. Despite this reduction, several other institutional investors increased their holdings in Kenvue. The company currently holds a consensus "Hold" rating from sell-side analysts with a price target of $19.58 and recently declared a quarterly dividend of $0.2075 per share.
Vanguard disaggregates holdings; KVUE filings show 0 shares after realignment (KVUE)
The Vanguard Group has filed an amended Schedule 13G/A for Kenvue Inc. (KVUE), reporting beneficial ownership of 0 shares, representing 0% of the class. This change follows an internal realignment on January 12, 2026, where several Vanguard subsidiaries will now report their holdings separately. The filing clarifies that Vanguard itself no longer holds beneficial ownership over these disaggregated securities.
Kenvue Brands Release Skincare Innovations at AAD’s Annual Meeting
Kenvue brands Neutrogena, Aveeno, and Rogaine are presenting new scientific data, innovative products, and 20 research abstracts at the 2026 American Academy of Dermatology (AAD) Annual Meeting. The focus is on advancements in skin health and beauty, addressing consumer concerns such as UV-induced damage, hydration, barrier support, and acne solutions. Key highlights include new vitamin C research, Hydro Boost and Oat formulas for sensitive skin, skin barrier-safe acne treatments, and BEMT sunscreen research for enhanced UV protection.
Neutrogena®, Aveeno® and Rogaine® Release New Dermatology Research and Clinical Skincare Innovations on Healthy Aging, Moisturization, Sun Protection and Acne
Neutrogena®, Aveeno®, and Rogaine® are showcasing new scientific advancements and product innovations at the 2026 American Academy of Dermatology Annual Meeting. Their research focuses on healthy aging, deep moisturization, acne solutions, and enhanced sun protection, including new UV filter technologies. The brands aim to deliver accessible, science-backed solutions co-designed with dermatologists and trichologists to address key consumer and healthcare provider concerns.
Neutrogena®, Aveeno® and Rogaine® release new dermatology research and clinical skincare innovations on healthy aging, moisturization, sun protection and acne
Neutrogena, Aveeno, and Rogaine are presenting new research and clinical innovations at the 2026 American Academy of Dermatology Annual Meeting. Their work focuses on healthy aging, moisturization for sensitive skin, effective acne management, and advanced sun protection technologies. The brands aim to provide science-backed, accessible solutions co-designed with dermatologists and trichologists.
Haleon plc stock faces consumer health sector headwinds amid global economic pressures and parent co
Haleon plc, a consumer healthcare company spun off from GSK, is navigating global economic pressures and shifting demand patterns while demonstrating resilience. The company relies on its strong portfolio of 21 powerbrands like Sensodyne and Panadol, which contribute to its robust financial health and consistent growth. Despite risks from inflation, competition, and supply chain disruptions, Haleon offers a defensive play for investors due to its essential health products and strategic focus on innovation and cost efficiencies.
Kenvue stock faces acquisition uncertainty as SG Americas boosts stake amid pending Kimberly-Clark d
Kenvue (NYSE:KVUE) faces acquisition uncertainty as SG Americas Securities LLC recently boosted its stake in the consumer health giant by nearly 3 million shares, totaling over 3 million shares worth about $53.1 million. This comes as Kenvue's acquisition by Kimberly-Clark, announced in November 2025, is pending closure in H2 2026. The stock, currently trading at $17.55, is 28% below its 52-week high, sparking interest among investors for potential value and arbitrage opportunities despite regulatory and integration risks.
Viking Fund Management LLC Sells 105,000 Shares of Kenvue Inc. $KVUE
Viking Fund Management LLC reduced its stake in Kenvue Inc. (NYSE:KVUE) by 17.4% in the fourth quarter, selling 105,000 shares and retaining 500,000 shares valued at $8.625 million. Kenvue exceeded Q4 earnings estimates with an EPS of $0.27 and revenue of $3.78 billion, and offers a quarterly dividend of $0.2075, resulting in a 4.7% yield. Analysts currently hold a "Hold" consensus rating for KVUE, with an average price target of $19.58.
Renaissance IPO ETF (IPO) Stock Price, Quote, News & History
This page provides a comprehensive overview of the Renaissance IPO ETF (IPO), including its current stock price, key statistics, news, and history. It details the ETF's investment policy, top holdings, and answers frequently asked questions about purchasing, competitors, forecasts, and dividends. The ETF tracks newly public companies on U.S. exchanges, aiming to capture a significant portion of the total market capitalization of recent IPOs.
SG Americas Securities LLC Buys 2,998,635 Shares of Kenvue Inc. $KVUE
SG Americas Securities LLC has significantly increased its stake in Kenvue Inc. (NYSE:KVUE) by purchasing an additional 2,998,635 shares, bringing its total holdings to 3,075,723 shares valued at approximately $53.1 million. Kenvue (KVUE) currently holds a consensus "Hold" rating from analysts with an average price target of $19.58, and offers a quarterly dividend yielding 4.7%, although its payout ratio is high at 107.79%.
Kenvue Inc. $KVUE Shares Sold by Assenagon Asset Management S.A.
Assenagon Asset Management S.A. significantly reduced its stake in Kenvue Inc. (NYSE:KVUE) by 38.8% in the fourth quarter, selling over 2.7 million shares and now owning approximately 0.23% of the company. Despite this, other institutional investors like American Century Companies Inc. and Independent Franchise Partners LLP increased their holdings. Kenvue recently reported strong Q4 earnings, surpassing analyst estimates, and announced a quarterly dividend, maintaining an average "Hold" rating from analysts with an average price target of $19.58.
Kenvue's Stock Dips 0.28% Amid 35.99% Volume Drop Ranking 443rd in Activity
Kenvue Inc. (KVUE) experienced a 0.28% stock drop, closing at $17.55, with trading volume significantly reduced by 35.99%. This decline is attributed to inconsistent earnings, revenue disappointments, and broader market conditions, despite the company's efforts in operational efficiency and a consistent dividend policy. Investors are now focused on the upcoming May 2026 earnings report for signs of a potential turnaround and improved sales momentum.
Kenvue's Stock Dips 0.28% Amid 35.99% Volume Drop Ranking 443rd in Activity
Kenvue Inc. (KVUE) experienced a 0.28% stock dip, closing at $17.55 on March 24, 2026, with a significant 35.99% drop in trading volume. This decline is attributed to inconsistent earnings, revenue disappointments, and macroeconomic headwinds despite the company's efforts in operational efficiency and maintaining dividend stability. Investors are keenly awaiting the May 2026 earnings report for signs of a turnaround.
Wedmont Private Capital Increases Stock Holdings in Kenvue Inc. $KVUE
Wedmont Private Capital significantly increased its stake in Kenvue Inc. (NYSE: KVUE) by 720.5% in the fourth quarter, now holding 83,827 shares valued at approximately $1.403 million. Other institutional investors also adjusted their holdings in Kenvue, which currently has a consensus "Hold" rating and an average price target of $19.58. Kenvue offers a 4.8% dividend yield but has a high payout ratio of 107.79%.
Kenvue Inc. stock rises Monday, outperforms market
Kenvue Inc. (KVUE) shares increased by 1.15% to $17.60 on Monday, outperforming the broader market. The S&P 500 Index and the Dow Jones Industrial Average also saw gains. This rise ended a three-day losing streak for the stock.
Understanding Momentum Shifts in (KVUE)
This article provides an analysis of Kenvue Inc. (KVUE) stock, indicating a near-term neutral sentiment that suggests a pause in its mid and long-term weakness. It highlights an exceptional risk-reward short setup and outlines three AI-generated trading strategies tailored for different risk profiles and holding periods, including position trading, momentum breakout, and risk hedging.
If You Invested $1,000 in Kenvue Inc. (KVUE)
This article examines the hypothetical returns of a $1,000 investment in Kenvue Inc. (KVUE) over various periods, showing a negative total return compared to the S&P 500. It also provides detailed information about Kenvue Inc., including its business focus on consumer health products like Tylenol and Listerine, its corporate developments such as leadership changes and strategic reviews, and the planned acquisition by Kimberly-Clark Corporation. The article highlights Kenvue's financial performance, use of non-GAAP measures, and investor information.
Hudson Bay Capital Management LP Buys 388,688 Shares of Kenvue Inc. $KVUE
Hudson Bay Capital Management LP has significantly increased its stake in Kenvue Inc. (NYSE:KVUE), purchasing an additional 388,688 shares in the third quarter, bringing its total holdings to 738,688 shares valued at approximately $11.99 million. Kenvue's recent earnings exceeded analyst estimates, and the company pays a quarterly dividend yielding about 4.8%. Analysts currently have a consensus "Hold" rating on Kenvue, with an average price target of $19.58.
Kenvue Inc. (NYSE:KVUE) Given Average Recommendation of "Hold" by Analysts
Kenvue Inc. (NYSE:KVUE) has received an average "Hold" recommendation from sixteen research firms, with thirteen analysts rating it as "hold" and three as "buy." The average twelve-month price target is fixed at $19.5833, based on recent analyst reports. The company recently reported quarterly earnings of $0.27 per share, topping estimates, and declared a quarterly dividend of $0.2075 per share, representing an annualized dividend of $0.83.
CIBC Bancorp USA Inc. Takes $11.51 Million Position in Kenvue Inc. $KVUE
CIBC Bancorp USA Inc. recently acquired a new position of 709,052 shares in Kenvue Inc. (NYSE:KVUE), valued at approximately $11.51 million, making it one of many institutional investors holding about 97.6% of the stock. Kenvue reported strong Q3 earnings, beating analyst expectations with $0.27 EPS and $3.78 billion in revenue, and offers a quarterly dividend despite a high payout ratio. Analysts currently maintain a consensus "Hold" rating for Kenvue with an average price target of $19.58, following mixed revisions to price targets by several firms.
What’s Driving Johnson & Johnson Stock?
Johnson & Johnson's stock rose 70% since early 2025, primarily due to a 60 percentage point expansion in its P/S multiple, with revenue growth contributing only 6 percentage points. This re-rating was driven by the Kenvue spin-off, a strong product pipeline, and expectations of margin expansion, transforming the company into a focused healthcare entity. However, ongoing talc litigation continues to act as a discount on its valuation.
Jacobs & Co. CA Sells 69,979 Shares of Kenvue Inc. $KVUE
Jacobs & Co. CA significantly reduced its stake in Kenvue Inc. (NYSE: KVUE) by 27.6% in the fourth quarter, selling 69,979 shares to hold 183,638 shares valued at approximately $3.17 million. Kenvue's stock opened at $17.52 and has a market capitalization of $33.58 billion, with a P/E ratio of 22.75. The company recently exceeded Q4 earnings expectations with EPS of $0.27 and revenue of $3.78 billion and has an average analyst rating of "Hold" with a $19.58 price target.
Kimberly-Clark Corp Stock (ISIN: US4943681035) Gains Ethical Recognition Amid Valuation Debate and Analyst Adjustments
Kimberly-Clark Corp (KMB) has been recognized as one of Ethisphere's 2026 World's Most Ethical Companies for the eighth time, boosting investor appeal for its stable dividend and ethical practices. While Piper Sandler trimmed its price target to $114, it maintained an Overweight rating, highlighting cost hedges through 2026. The company is undergoing portfolio reshaping and trades at a perceived discount, offering a 5.15% dividend yield, making it attractive for defensive and ethical investors.
Fortune Brands CEO never officially worked a day—but he’ll get $18.4 million after a massive leadership shakeup
Amit Banati, designated CEO of Fortune Brands Innovations, will receive $18.4 million in cash despite never officially working a day in the role following a leadership shakeup influenced by an activist investor. This "make whole" payment compensates him for compensation he left behind at his previous company, Kenvue. The situation arose after activist investor Ed Garden acquired a stake and nominated new board members, leading to a cooperation agreement and a comprehensive search for a new CEO.
Kenvue Inc. stock falls Wednesday, underperforms market
Kenvue Inc. (KVUE) shares fell 1.46% to $17.51 on Wednesday, breaking a three-day winning streak. This decline occurred during a broader market downturn, with the S&P 500 Index (SPX) and Dow Jones Industrial Average (DJIA) also experiencing significant losses. The stock underperformed the overall market.
Canaccord Genuity and Barclays raise Kenvue (KVUE) price targets
Canaccord Genuity and Barclays have both increased their price targets for Kenvue (KVUE). Despite a recent dip in KVUE shares, analysts remain optimistic about the company's future performance. This uplift in price targets suggests an anticipated positive trajectory for Kenvue's stock.
Kenvue (KVUE) executive exercises 6,157.82 RSUs and retains all shares
Kenvue (KVUE) Group President EMEA & LA, Carlton Lawson, exercised 6,157.82 restricted stock units (RSUs) on March 10, 2026, converting them into common stock. He retained all shares, paying taxes in cash, which prevented any share withholding. Following this transaction, Lawson directly holds 111,415.02 shares of Kenvue common stock, in addition to 12,313.63 RSUs.
Mason Capital Management LLC Acquires New Position in Kenvue Inc. $KVUE
Mason Capital Management LLC has acquired a new position in Kenvue Inc. (NYSE:KVUE), purchasing 2,595,000 shares valued at approximately $42.12 million in Q3, making it the fund's second-largest holding. Wall Street analysts have a "Hold" consensus rating with an average price target of $19.58, influenced by mixed analyst revisions. Kenvue recently exceeded EPS estimates and reported a 3.2% increase in revenue, while also declaring a quarterly dividend yielding about 4.7%.
California Public Employees Retirement System Buys 1,137,317 Shares of Kenvue Inc. $KVUE
The California Public Employees Retirement System increased its stake in Kenvue Inc. (NYSE:KVUE) by 35.1% in the third quarter, purchasing over 1.1 million additional shares, bringing its total holdings to 4,379,740 shares valued at approximately $71.08 million. Kenvue, a consumer health company, has a consensus "Hold" rating from analysts with an average price target of $19.58, and recently reported strong quarterly earnings, beating both EPS and revenue estimates. Despite paying a 4.7% dividend, concerns exist regarding its high payout ratio of 107.8%, while institutional investors hold a significant 97.64% of the stock.
What Kenvue (KVUE)'s Broad Q4 Rebound and Kimberly‑Clark Talks Mean For Shareholders
Kenvue (KVUE) reported stronger-than-expected Q4 and full-year 2025 results, with all three business segments showing year-over-year growth, primarily driven by strong execution and progress towards a potential combination with Kimberly‑Clark. This broad-based recovery and strategic discussions are reshaping investor perceptions of Kenvue’s consumer health platform. The company's investment narrative centers on translating brand strength into consistent cash generation while simplifying operations and focusing on digital innovation.
Kenvue Inc. stock rises Monday, outperforms market
Kenvue Inc. (KVUE) saw its stock rise by 1.26% to $17.71 on Monday, marking its second consecutive day of gains. This performance outperformed the broader market, as the S&P 500 Index (SPX) increased by 1.01% and the Dow Jones Industrial Average (DJIA) rose by 0.83% on the same trading day.
Kenvue promotes pair to internal, external comms leads
Kenvue has appointed Melissa Witt as VP and head of global external communications and Kristen Wallace as VP and head of internal communications and comms integration lead. Both Witt and Wallace previously held various communications roles at Johnson & Johnson and Kenvue, which was spun off from J&J in 2023. This announcement follows Kenvue's recent restructuring efforts and its upcoming acquisition by Kimberly-Clark in the second half of 2026.
